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Aims The recent availability of the novel oral anticoagulants (NOACs) may have led to a change in the anticoagulation regimens
of patients referred to catheter ablation of atrial fibrillation (AF). Preliminary data exist concerning dabigatran, but infor-
mation regarding the safety and efficacy of rivaroxaban in this setting is currently scarce.
Methods
and results
Of the 556 consecutive eligible patients (age 61.0+ 9.6; 74.6% men; 61.2% paroxysmal AF) undergoing AF catheter ab-
lation in our centre (October 2012 to September 2013) and enroled in a systematic standardized 30-day follow-up
period: 192 patients were under vitamin K antagonists (VKAs), 188 under rivaroxaban, and 176 under dabigatran.
Peri-procedural mortality and significant systemic or pulmonary thromboembolism (efficacy outcome), as well as bleed-
ing events (safety outcome) during the 30 days following the ablation were evaluated according to anticoagulation
regimen. During a 12-month time interval, the use of the NOACs in this population rose from ,10 to 70%. Overall,
the rate of events was low with no significant differences regarding: thrombo-embolic events in 1.3% (VKA 2.1%; rivar-
oxaban 1.1%; dabigatran 0.6%; P ¼ 0.410); major bleeding in 2.3% (VKA 4.2%; rivaroxaban 1.6%; dabigatran 1.1%;
P ¼ 0.112), and minor bleeding 1.4% (VKA 2.1%; rivaroxaban 1.6%; dabigatran 0.6%; P ¼ 0.464). No fatal events were
observed.
Conclusion The use of the NOAC in patients undergoing catheter ablation of AF has rapidly evolved (seven-fold) over 1 year. These
preliminary data suggest that rivaroxaban and dabigatran in the setting of catheter ablation of AF are efficient and safe,
compared with the traditional VKA.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Atrial fibrillation † Rivaroxaban † Dabigatran † Vitamin K antagonists † Fluindione † Stroke † Cryoablation †
Thromboembolism † Bleeding † Arrhythmia
Introduction
Atrial fibrillation (AF) is the most frequent sustained arrhythmia in clin-
ical practice.1 Catheter ablation of AF has been established as the most
effective therapy for the treatment of symptoms in these patients.2
However, this procedure is associated with a significant thrombo-
embolic risk during and shortly after the procedure, requiring an
effective anticoagulation.3 Vitamin K antagonists (VKA) have been
traditionally used to prevent procedure-related thromboembolism.4
Recently, noval oral anticoagulants (NOACs) offering important
advantages beyond their easiness of administration, like less interac-
tions and no need of laboratory monitoring, have become available
and appear as an attractive alternative in this setting. The impact of
the wide availability of these NOACs in preventive anticoagulant
treatment of patients that are currently being referred to catheter ab-
lation of AF is currently unknown.
Dabigatran (a direct thrombin inhibitor) has displayed reassuring
safety and efficacy data, suggesting that it might be used as an alterna-
tive to VKA.5,6 However, data are almost absent concerning rivarox-
aban, another NOAC with a different mechanism of action (a factor
Xa inhibitor) which is being increasingly used worldwide.
Aim
We aimed to: (i) observe the change in the pattern of anticoagulant
prescription in patients referred for catheter ablation of AF in our
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centre since the introduction of the NOAC; (ii) assess the efficacy
and safety of dabigatran and rivaroxaban in patients referred for cath-
eter ablation of AF compared with VKA.
Methods
Prospective, non-randomized, single-centre, observational study evalu-
ating the efficacy and safety of different anticoagulation regimens in the
setting of catheter ablation of AF.
Study sample
All consecutive patients undergoing catheter ablation of AF from
October 2012 to September 2013 in Clinique Pasteur, Toulouse,
France, were assessed for possible inclusion in this investigation. All
patients with paroxysmal and non-paroxysmal forms, undergoing first
or redo procedures and planned for treatment with radiofrequency or
cryoballoon ablation were considered eligible.
Participants needed to be on effective oral anticoagulation (VKA, dabi-
gatran, or rivaroxaban) for at least 30 days before the procedure to be
considered for inclusion. Patients treated only with antiplatelet agents
or subcutaneous heparin before the procedure were excluded from
the analysis. On the other hand, if patients had been treated with one
of the NOACs and due to intolerance to the drug needed to be
changed to a different oral anticoagulant (namely if the changing was
already planned before the procedure), they were excluded from the
analysis.
Patients treated with VKA before the procedure that were changed to
dabigatran and rivaroxaban on the day of the procedure, and those
treated with VKA, dabigatran, and rivaroxaban before the procedure,
and remaining on the same drug after the procedure were considered
eligible for analysis.
Information on baseline CHADS2, CHA2DS2-VASc, HAS-BLED, and
other clinical data was retrieved. Vascular disease was defined as having
at least one of the following: myocardial infarction, peripheral artery
disease, or complex aortic plaque.
Computed tomography scan (64-slice Siemens&dual source CT scan)
was performed in 24 h prior to the procedure for assessing pulmonary
vein and left atrial anatomy and to exclude the presence of thrombi in
the left atrial appendage. Transthoracic echocardiography was also per-
formed in all the patients for assessing left atrial dimensions, left ventricle
ejection fraction, and the presence of valvular heart disease.
All patients provided an informed consent prior to the procedure. The
study complied with the Declaration of Helsinki and the research proto-
col was approved by the local ethics committee.
Peri-procedural anticoagulation
According to the type of peri-procedural anticoagulation, the study sam-
ple was divided into three groups (Figure 1): Group A—treated with
VKA before and after the procedure; Group B—rivaroxaban or VKA
before and rivaroxaban started on the day of the procedure; Group
C—dabigatran or VKA before and dabigatran started on the day of the
procedure.
Vitamin K antagonists were stopped 5 days before the procedure in all
the patients and subcutaneous heparin (either calcium heparin 10 000 IU
twice a day (bid) or enoxaparin 1 mg/kg bid, or 0.5 mg/kg bid if chronic
kidney disease was present) was started 48 h after.
Dabigatran was interrupted 24–36 h before the procedure. The inter-
ruption in patients treated with rivaroxaban occurred 24–48 h before the
What’s new?
† We demonstrate that the use of the novel oral anticoagulants
in patients undergoing catheter ablation of atrial fibrillation has
rapidly evolved (seven-fold) over 1 year.
† We provide the largest data to date concerning the safety and
efficacy of rivaroxaban in the setting of catheter ablation of
atrial fibrillation.
† The incidence of bleeding and thrombo-embolic events was
low with all treatment regimens (rivaroxaban, dabigatran,
and vitamin K antagonists), with no significant differences
being found.
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Figure 1 Flowchart illustrating the different treatment regimens
and timing of drug interruption and restart, as well as bridging
heparin therapy.
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ablation. In some patients, an earlier interruption was possible due to the
presence of comorbidities (like chronic kidney disease) or physician prefer-
ence due to other reasons. Subcutaneous heparin was started 24 h after the
interruption of rivaroxaban. In patients treated with dabigatran, subcutane-
ousheparinwas started12 hafter suspensionof thedrugexcept forpatients
with estimated glomerular filtration rate below 45 mL/min, where subcuta-
neous heparin was started only 24 h after dabigatran interruption.
Vitamin K antagonists were restarted in the evening of the procedure.
Dabigatran and rivaroxaban were started 4–6 h after the procedure. No
protamine was administered at the time of sheath removal. After the pro-
cedure, subcutaneous heparin was continued only in patients treated with
VKA and until international normalized ratio (INR) values were over 2.0.
Catheter ablation
All patients received general anaesthesia.
Venous punctures were performed: three for radiofrequency proce-
dures (a 8Fr sheath and a 8Fr and 7Fr introducer) and two for cryoballoon
ablation (a steerable 12Fr sheath (Flexcathw, Medtronic&, and a 7Fr intro-
ducer) and the multipolar irrigated radiofrequency catheter nMARQTM,
Biosense Webster&,) (8.5Fr sheath). By using a transfemoral venous ap-
proach, a quadripolar catheter was placed in the coronary sinus. A single
transseptal puncture was performed under fluoroscopic guidance (with use
of transoesophageal echocardiography only if no success was obtained with
fluoroscopy).Uponcompletionof the transseptalpuncture,patients received
intravenous heparin to maintain an activated clotting time of.300 s.
Patients underwent standard ablation procedures as directed by the
operator. These procedures included pulmonary vein isolation with or
without additional substrate modification. Ablation catheters used
included cryothermic balloon catheter (Arctic Frontw, Arctic Front
Advancew, Medtronic, Inc.) and open-irrigated catheters: Celsius Ther-
mocoolw, EZsteer Thermocoolw, SmartTouchw, nMARQw (Biosense
Webster), Tacticathw (St Jude Medical).
Thrombo-embolic and bleeding events
The following safety and efficacy endpoints were assessed, using the cri-
teria proposed by Sorgente et al.:7
(1) All-cause peri-procedural death.
(2) Thromboembolism—acompositeof stroke, transient ischaemicattack
(TIA), systemic or pulmonary embolism. A stroke was defined as a
sudden focal neurological deficit of presumed cerebrovascular aeti-
ology lasting for.24 h, not due to another identifiable cause and con-
firmedbycomputed tomographyormagnetic resonance imagingof the
brain. If symptoms were short lasting (,24 h) and no evidence of ne-
crosis was found on brain imaging, the event was considered to be a
TIA. A systemic embolic event was defined as an abrupt vascular insuf-
ficiency associated with clinical or radiological evidence of arterial oc-
clusion in theabsenceof another likelymechanism(e.g. atherosclerosis,
instrumentation, or trauma). A pulmonary embolism was diagnosed
when dyspnoea or other suggestive clinical presentation was accom-
panied by a radiological confirmation of a new pulmonary perfusion
of intra-luminal defect, according to the requisitesof the latest pulmon-
ary embolism European Society of Cardiology guidelines.8
(3) Major bleeding—comprising cardiac tamponade, bleeding necessitat-
ing intervention (either thrombin injection or surgery) or transfusion,
massive haemoptysis, haemothorax, retroperitoneal bleeding, or any
other life-threatening bleed leading to prolongation of hospitalization.
(4) Minor bleeding—defined as puncture site bleeding, thigh ecchymosis
or haematoma, pericardial effusion with no haemodynamic com-
promise, minor gastrointestinal bleeding, epistaxis, or any bleeding
treated conservatively with no need for transfusion, surgery, or pro-
longed hospitalization.
We highlight that these criteria for defining major and minor bleeding are
strongly based on the International Society on Thrombosis andHaemostasis,9
but adapted to the catheter ablation of AF setting.
Other complications were also reported when the investigators
judged that these might possibly be associated with peri-procedural
anticoagulation.
Follow-up was obtained for the first 30 days after the procedure for all
the patients and was either obtained after an observation of each patient
at our centre or by a report from the patient’s assistant cardiologist con-
cerning that time period. Patients and their assistant cardiologists were
instructed to report to the study centre immediately if any of these
events occurred.
Statistical analysis
Comparisons were performed between the different peri-procedural antic-
oagulation regimens. x2 was used for the comparison of nominal variables.
One-way analysis of variance (ANOVA), or its non-parametric equivalent,
Kruskal–Wallis when appropriate, was used for comparison of continuous
variables; the Levene’s test was used to check the homogeneity of the vari-
ance. Results with P, 0.05 were regarded as significant.
When overall significant differences were found in the overall assess-
ment of the three treatment groups, direct comparisons among the differ-
ent groups were performed. Post hoc testing of ANOVAwas performed by
using the least significantdifferencetest.WhentheKruskal–Wallis testwas
used, post hoc was performed using the Mann–Whitney test. When com-
paring two categorical variables in post hoc, the x2 test was used, unless the
observed value in any of the 2 × 2 contingency table cells was ,5. In this
case, the Fisher’s exact test was used. The Bonferroni correction was used
for estimating the significant P value for multiple comparisons. PASW Sta-
tistics (SPSS Inc.) version 18.0 was used for descriptive and inferential stat-
istical analysis.
Results
Study sample and anticoagulation
Out of a total of 580 AF ablation procedures performed during the
inclusion period, the following 24 were excluded from analysis: 6
due to lack of oral anticoagulation in the previous month (2 patients
treated with aspirin, 2 with enoxaparin, and 2 with no thrombopro-
phylaxis); two patients were changed from the NOAC (one rivarox-
aban and one dabigatran) into warfarin at the time of ablation due to
previously known drug intolerance; 14 patients with intolerance to
dabigatran were changed to rivaroxaban and 2 patients with rivarox-
aban intolerance changed the treatment to dabigatran.
Of the remaining 556 patients included in the analysis, 192 were
included in Group A (treatment with VKA), 188 in Group B (treat-
ment with rivaroxaban), and 176 in Group C (treatment with dabiga-
tran). Vitamin K antagonists were used before the procedure in 86 of
the patients (45.7%) treated with rivaroxaban and 68 (38.6%) of
those treated with dabigatran (Figure 2).
Fluindione was the most frequently used VKA (86% in Group A;
40% in Group B; 32% in Group C). Only a minority of patients
were treated with other VKA. Warfarin was used in 20 patients in
Group A (10.4%), 8 patients in Group B (4.3%), and 10 patients
in Group C (5.7%). Acenocumarol was used in seven patients in
Group A (3.6%), two patients in Group B (1.1%), and two patients
in Group C (1.1%).
Rivaroxaban 15 mg id was used in three patients before and in
seven patients after the procedure. The 20 mg id dosage was used
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in all of the remaining patients. Dabigatran 110 mg bid was used in 22
patients before and 17 patients after the procedure. The 150 mg bid
dosage was used in all of the remaining patients.
In a small percentage of patients, the NOACs were suspended
earlier (4–5 days before the procedure) than described in Figure 1
(12 patients treated with dabigatran and 17 patients treated with
rivaroxaban). This occurred due to physician’s preference in the
first months of utilization, in procedures that were anticipated to
havehighercomplexity, and inpatientswith compromised renal func-
tion. Despite the small number of patients in this situation, a similar
efficacy and safety profile was found in this subset.
Some differences were found atbaseline among the three different
treatment groups (Table 1). Patients treated with VKA and rivaroxa-
ban only differed in terms of age (a 3-year difference, with VKA
patients being older). Patients treated with rivaroxaban were
similar at baseline when compared with those treated with dabiga-
tran, except for a lower bleeding risk (HAS-BLED) in the dabigatran
group. Differences at baseline were more pronounced in the VKAvs.
dabigatran comparison: higher prevalence of persistent AF, older
patients, higher body mass index, higher thrombo-embolic and
bleeding risk, more hypertensive patients, and lower baseline
haemoglobin in the VKA group.
No differences were found concerning the use of antiplatelet
agents before and after the procedure (Table 2). All patients
treated with VKA before the ablation performed bridging therapy
with subcutaneous heparin (mainly calcium heparin). However, in
patients suspending rivaroxaban (n ¼ 27) and dabigatran (n ¼ 46)
24 h or less before the procedure, no subcutaneous heparin bridging
was performed. The differences found in the concomitant use of sub-
cutaneous heparin in the different groups are explained by the differ-
ent half-life of the three agents and consequently the timing of
interruption before the procedure.
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Figure 2 Evolution of the type of anticoagulants used at the
arrival of our centre from October 2012 to September 2013 in
patients admitted for AF ablation. VKA, vitamin K antagonists.
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Table 1 Baseline overall sample and characterization of each treatment group
Overall
(n5 556)
VKA
(n5 192)
Rivaroxaban
(n 5 188)
Dabigatran
(n 5 176)
Overall
P
Subgroup comparisons
Paroxysmal AF 61.2% (340) 52.6% (101) 63.3% (119) 68.2% (120) 0.007 VKA vs. dabigatran
Age 61.0+9.5 62.9+8.3 60.1+9.9 59.8+9.8 0.002 VKA vs. dabigatran, VKA vs.
rivaroxaban
Female gender 25.4% (141) 26.0% (50) 26.1% (49) 23.9% (42) 0.859
Body mass index 27.6+4.4 28.3+4.6 27.3+4.2 27.2+4.5 0.031 VKA vs. dabigatran
CHADS2 0.8+0.9 0.9+1.0 0.8+1.0 0.5+0.8 0.001 VKA vs. dabigatran
CHA2DS2-VASc 1.5+1.3 1.8+1.4 1.5+1.3 1.2+1.2 0.001 VKA vs. dabigatran
HAS-BLED 1.0+0.9 1.1+0.9 1.0+0.9 0.7+0.8 0.001 VKA vs. dabigatran,
rivaroxaban vs. dabigatran
Hypertension 39.6% (220) 49.0% (94) 39.4% (74) 30.1% (53) 0.001 VKA vs. dabigatran
Diabetes mellitus 8.8% (49) 10.9% (21) 9.0% (17) 6.3% (11) 0.282
Previous stroke of TIA 9.4% (52) 10.4% (20) 11.2% (21) 6.3% (11) 0.225
Glomerular filtration rate
(Cockroft–Gault)
74.3+23.7 73.6+27.3 74.1+20.9 75.3+22.3 0.783
Baseline C-reactive protein
(mg/L)
3.7+5.2 3.6+4.7 4.0+5.8 3.4+5.1 0.637
Baseline haemoglobin (g/dL) 14.7+1.3 14.6+1.3 14.7+1.2 15.0+1.2 0.029 VKA vs. dabigatran
Indexed left atrial volume
(mL/m2)
45.7+16.5 47.6+17.1 45.3+18.1 44.1+13.9 0.172
Left ventricular ejection
fraction (%)
62.4+8.7 61.6+10.2 61.9+8.3 63.9+7.0 0.125
VKA, vitamin K antagonists; AF, atrial fibrillation; TIA, transient ischaemic attack.
Reference values for haemoglobin: 13.5–17.5 g/dL; C-reactive protein: ,3.00 mg/L.
The observed differences were significant for the following subgroup comparisons: VKA vs. dabigatran; VKA vs. rivaroxaban; Rivaroxaban vs. dabigatran.
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The length of the procedure was longer in the VKA group than in
the NOACs. However, the time difference (when comparing proce-
dures with dabigatran or rivaroxaban vs. VKA) was more pro-
nounced in the dabigatran group (20 min) than in patients treated
with rivaroxaban (10 min).
Safety and efficacy of the different drug
regimens
A low overall rate of thrombo-embolic events and complications was
observed (Table 3). No patients died during the follow-up period. No
significant differences in the rate of events were found among the
three treatment groups.
An overall low incidence (0.9%) of stroke was reported. Four
strokes were observed in the VKA group (2.1%) and another one
was observed in a patient treated with rivaroxaban (0.5%) (see
Supplementary material online, Table S4). These either left no
sequels or led to minor disability at the end of the 30-day follow-up
period. However, puncture complications filling major bleeding cri-
teriawereobserved in all the groups, ranging from1 to 3% of patients.
A 1% incidence of pericardial effusion justifying pericardiocentesis or
hospitalization/changes in therapy was observed in patients treated
VKA and in one patient (0.5%) treated with rivaroxaban. A low inci-
dence (1.4%) of minor bleeding (haematoma) was observed.
Onepatient treatedwithdabigatrandevelopedanatrio-oesophageal
fistula and one patient treated with VKA presented oesophageal ulcer-
ation after cryoballoon ablation (see Supplementary material online,
Table S4).
The use of cryoballoon ablation was not associated with a signifi-
cant increase in minor bleeding (2.4 vs. 1.0%; P ¼ 0.243) or major
bleeding-related puncture complications (1.8 vs. 1.8%; P ¼ 1.0), in
spite of the larger diameter sheaths required for this technique.
Grouping dabigatran and rivaroxaban in one variable, a similar
incidence of thrombo-embolic events (0.8% NOAC vs. 2.1% VKA;
P ¼ 0.205) and minor bleeding (1.1% NOAC vs. 2.1% VKA;
P ¼ 0.354) were observed when compared with VKA. Despite the
presence of a higher incidence of major bleeding events in the
VKA group on univariate analysis (4.2% VKA vs. 1.4% NOAC;
P ¼ 0.038), after adjusting for all baseline differences, VKA were
not independent predictors of major bleeding on multivariate
analysis.
Discussion
We present reassuring preliminary data in support of the efficacy and
safetyof rivaroxaban in the setting of catheter ablation of AF. Further-
more, the low complication rate from patients previously treated
with VKA that were changed to the NOAC at the time of catheter
ablation of AF seems to provide support to this practice.
Despite the slight differences in some baseline (mainly between
the VKA and dabigatran group, impairing possible comparisons
between these two agents, which was also not the aim of this
work) and intra-procedural aspects, already highlighted in the previ-
ous section, ourdata seemto suggest anoverall lowevent ratewith all
treatment regimens. Furthermore, similar baseline characteristics
allow a legitimate comparison of rivaroxaban with both VKA and
dabigatran.
As shown in these data, patients are being referred more frequent-
ly to catheter ablation centres under treatment with the NOAC.
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Table 2 Procedural and medication aspects in the overall sample and each treatment group
Overall
(n 5 556)
VKA
(n 5 192)
Rivaroxaban
(n5 188)
Dabigatran
(n 5 176)
Overall
P
Subgroup comparisons
Antiplatelet agent before the
procedure
0.190
Aspirin 7.0% (39) 9.4% (18) 6.9% (13) 4.5% (8)
Clopidogrel 0.9% (5) 0.5% (1) 1.6% (3) 0.6% (1)
Aspirin + clopidogrel 0.4% (2) 1.0% (2) 0% 0%
Antiplatelet agent after the
procedure
0.197
Aspirin 3.8% (21) 5.7% (11) 3.7% (7) 1.7% (3)
Aspirin + clopidogrel 0.2% (1) 0.5% (1) 0% 0%
Subcutaneous heparin
bridging
0.001 VKA vs. rivaroxaban, VKA vs.
dabigatran, rivaroxaban vs.
dabigatranLMWH 15.1% (84) 6.3% (12) 27.7% (52) 11.4% (20)
Calcium heparin 71.8% (399) 93.8% (180) 58.0% (109) 62.5% (110)
Cryoablation 29.5% (164) 33.3% (64) 31.9% (60) 22.7% (40) 0.056
Redo procedure 22.8% (127) 25.0% (48) 24.5% (46) 18.8% (33) 0.292
Procedure duration 134.8+47.3 145.3+54.5 132.4+39.1 125.4+44.3 0.001 VKA vs. rivaroxaban, VKA vs.
dabigatran
Fluoroscopy duration 24.9+9.7 26.9+10.4 23.8+9.2 23.8+9.0 0.004 VKA vs. rivaroxaban, VKA vs.
dabigatran
VKA, vitamin K antagonists; LMWH, low-molecular-weight heparin.
The observed differences were significant for the following subgroup comparisons: VKA vs. rivaroxaban; VKA vs. dabigatran; Rivaroxaban vs. dabigatran.
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However, if a solid bodyof evidence has been gathered for dabigatran
supporting its use as an alternative to VKA (almost 2000 patients in a
recently published meta-analysis5), data had been almost absent for
rivaroxaban until now. To the best of our knowledge, this is the
largest series of patients managed with rivaroxaban in the setting of
catheter ablation of AF.
Eitel and colleagues have provided data on 16 patients who under-
went AF ablation and were treated with rivaroxaban 20 mg id.
However, two of these patients had been treated with subcutaneous
low-molecular-weight heparin and one patient had no anticoagula-
tion prior to the procedure.10
There is also information from a subanalysis of the ‘Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibition Compared with
Vitamin K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation’ (ROCKET-AF) trial, assessing the out-
comes after cardioversion and AF ablation. The incidence of
stroke or systemic embolism after electrical cardioversion, pharma-
cological cardioversion, and catheter ablation of AF was 0.93%.
However, no specific information exists concerning the 79 patients
who underwent 85 AF ablation procedures in the trial, peri-
procedural drug regimen, and the event rate in each treatment
arm.11
Further data will certainly be provided by the still ongoing ‘A Study
Exploring Two Treatment Strategies in PatientsWith Atrial FibrillationWho
Undergo Catheter Ablation Therapy’ (VENTURE-AF trial), comparing
rivaroxaban and warfarin, which estimates an enrolment of 200
patients.12
Our data show that some thrombo-embolic events occurred in
patients with low risk as illustrated by the CHADS2 and CHA2DS2-
VASc scores (see Supplementary material online, Table S4), which
highlights the low acuity of these scores for predicting events in this
setting and also suggests that these complications may be more
strongly related to the procedure than to the overall baseline
thrombo-embolic risk of each patient. Also, it is legitimate to think
that the mechanism of thrombus formation after an ablation
procedure may be different to that happening naturally in AF and
be more related to the extension of left atrial endothelial lesion/
denuded left atrial wall. Therefore, it is of utmost importance to
assure therapeutic anticoagulation levels right after the procedure.
The overall rate of complications in this sample was lowand similar
to what has been described in a series of .93 000 procedures from
2000 to 2010, that reported an intra-hospital rate of stroke or TIA of
1.02%, pericardial complications in 1.53%, and vascular complications
in 1.52%.13
Previously published data suggest that prolonged interruption of
dabigatran in this setting may lead to an increase in thrombo-embolic
complications.14 In our sample, the patient who presented a stroke
on treatment with rivaroxaban had suspended the drug 4 days
before the procedure and despite being on subcutaneous calcium
heparin, we wonder if the same principle may also apply to this
drug. However, the low rate of events and the low numberof patients
with a long interruption of rivaroxaban in our sample donot allowthe
making of such inference.
The overall incidence of atrio-oesophageal fistula after catheter
ablation of AF is thought to be rare.15 Despite the presence of
reports of oesophagitis as a possible complication of therapy with
dabigatran (out of the context of catheter ablation), due to the pres-
ence of tartrate as an excipient,16 no strong conclusions can be drawn
towards acausal effect in the patientpresented in our sample, the first
reported case of a patient developing an atrio-oesophageal fistula
while on treatment with this drug.
In this paper, we assessed the role of the NOACs when used
before and after the procedure. However, since 38–45% of patients
in the dabigatran and the rivaroxaban groups, respectively, were
treated with VKA before the procedure and changed to the
NOACs at the time of the procedure, more robust data are provided
regarding the post-procedural period. Furthermore, despite the
scarcity of data regarding the initiation of a direct thrombin inhibitor
or a Factor Xa inhibitor after ablation, this has been proposed in the
2012 Heart Rhythm Society/European Heart Rhythm Association/
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Events observed during the 30-day follow-up period
Overall (n5 556) VKA (n5 192) Rivaroxaban (n5 188) Dabigatran (n5 176) P
All-cause mortality 0% 0% 0% 0% N.A.
Thromboembolism 1.3% (7) 2.1% (4) 1.1% (2) 0.6% (1) 0.410
Stroke 0.9% (5) 2.1% (4) 0.5% (1) 0%
TIA 0.4% (2) 0% 0.5% (1) 0.6%(1)
Pulmonary embolism 0% 0% 0% 0%
Systemic embolism 0% 0% 0% 0%0
Major bleeding 2.3% (13) 4.2% (8) 1.6% (3) 1.1% (2) 0.112
Puncture complications 1.8% (10) 3.1% (6) 1.1% (2) 1.1% (2)
Pericardial effusion 0.5% (3) 1.0% (2) 0.5% (1) 0%
Minor bleeding 1.4% (8) 2.1% (4) 1.6% (3) 0.6% (1) 0.464
Haematoma 1.4% (8) 2.1% (4) 1.6% (3) 0.6% (1)
Other complications 0.4% (2) 0.5% (1) 0% 0.6% (1) 0.398
Atrio-oesophageal fistula 0.2% (1) 0% 0% 0.6% (1)
Oesophageal ulcer 0.2% (1) 0.5% (1) 0% 0%
VKA, vitamin K antagonist; TIA, transient ischaemic attack; N.A., not applicable.
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European Cardiac Arrhythmia Society Expert Consensus Statement
on catheter and surgical ablation of AF.3
In our study, we have interrupted the NOACs 24–48 h before the
procedure. However, there seems to be a growing trend for shorter
interruption times. In some recent investigations, it has been inter-
ruptedeither thenightbefore theprocedure,17 orevennot interrupted
at all.18
Limitations
Although we report the fist large prospective evaluation of rivarox-
aban in the setting of catheter AF ablation, we agree that this investi-
gation has several limitations which need to be discussed. First, our
observational and non-randomized single-centre data result from a
small sample of patients, but despite this provide the larger body of
evidence available until now.
Secondly, subcutaneous calcium heparin and fluindione were
used in a relevant number of patients. These drugs are not common-
ly used in other countries and no direct comparative studies exist in
this context with the enoxaparin and warfarin, the drugs most widely
used and with larger evidence. However, the European Society of
Cardiology 2012 update of the AF guidelines19 and the recent
Venice Consensus on AF ablation20 refer to VKA as the recom-
mended treatment, not defining if warfarin or other drugs are
used. Also, fluindione has been widely used in France for decades
(it constitutes 80% of VKA prescription21) and no data exist that
suggest a higher incidence of events while on this drug. Also,
unlike warfarin, fluindione is not a racemic mixture and its longer
half-life is thought to help stabilize INR levels.22 For all these
reasons, this point should not be considered as a true limitation
but rather a particularity.
Thirdly, unlike other centres where ablation is performed under
uninterrupted VKA anticoagulation due to a possible reduction in
peri-procedural complications,23 our centre has been performing
these procedures using subcutaneous heparin bridging for over 10
years. However, in the aforementioned Consensus, there is no sug-
gestion or recommendation for choosing uninterrupted VKA over
the VKA interruption.3,20 Furthermore, our practice reflects a local
preference, among most French centres, of interrupted VKA,
which is also preferred by our anaesthetists. A possible criticism is
that we did not compare rivaroxaban with VKA at their best.
However, patients treated with the NOAC also suspended treat-
ment at the time of the procedure.
Fourthly, we have used heparin bridging after the interruption of
the NOAC. Most available investigations with dabigatran did not
use heparin bridging. Therefore, it is not yet known which should
be the preferred option, as besides the lack of evidence or compara-
tive trials, no recommendations exist regarding this point.
Fifthly, the baseline differences found in some of the three treat-
ment groups may impair subgroup comparisons as previously men-
tioned. However, if we look carefully to Supplementary material
online, Table S4, we can notice that not all seven patients sustaining
thrombo-embolic events had a high CHADS2 score: four patients
had a CHADS score of 0, two patients a CHADS score of 1, and
one patient a score of 3. Similarly, regarding the bleeding complica-
tions: for example, in the three observed pericardial effusions, two
had a HAS-BLED score of 0 and one had a score of 2.
Lastly, the overall low number of events did not allowassessing the
association of the different anticoagulation regimens with the out-
comes on multivariate analysis.
Conclusion
Since the introduction of the NOAC, patients are being referred for
catheter ablation of AF under treatment with these agents with in-
creasing frequency: from 10 to 70% over a 1-year period.
Our preliminary data suggest that NOAC in the setting of catheter
ablation of AF are as efficient and safe, compared with the traditional
VKA management.
However, despite being reassuring, these preliminary data need to
be replicated in future randomized trials.
Supplementary material
Supplementary material is available at Europace online.
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